Experiences and preferences about information on treatment-related side effects among patients with early breast cancer

被引：0

作者：

Di Meglio, Antonio ^{[1
]}

Catanuto, Giuseppe ^{[2
,3
]}

Zambon, Marzia ^{[4
]}

Chan, Alexandre ^{[5
]}

Kassianos, Angelos P. ^{[6
]}

Cloconi, Constantina ^{[7
,8
]}

Rohr, Silvia ^{[9
]}

Steele, Rebecca ^{[9
]}

Coersmeyer, Monique ^{[10
,11
]}

Ujupan, Sonia ^{[10
,11
]}

Peccatori, Fedro ^{[12
]}

机构：

[1] Gustave Roussy, Canc Survivorship Program, INSERM Unit 981, Villejuif, France

[2] European Soc Surg Oncol ESSO, Brussels, Belgium

[3] Human Ist Clin Catanese, Misterbianco, Catania, Italy

[4] Europa Donna The European Breast Canc Coalit, Milan, Italy

[5] Univ Calif Irvine, Sch Pharm & Pharmaceut Sci, Irvine, CA USA

[6] Cyprus Univ Technol, Dept Nursing, Limassol, Cyprus

[7] European Oncol Nursing Soc, Brussels, Belgium

[8] German Oncol Ctr, Limassol, Cyprus

[9] Vintura BV, Utrecht, Netherlands

[10] Eli Lilly & Co, Brussels, Belgium

[11] Vernier, Brussels, Switzerland

[12] IRCCS, European Inst Oncol, Milan, Italy

来源：

BREAST | 2025年 / 80卷

关键词：

QUALITY-OF-LIFE; ENDOCRINE THERAPY; SURVIVORS; IMPACT; WOMEN; CARE;

D O I：

10.1016/j.breast.2025.104414

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treatment-related side effects are common among women treated for early breast cancer and their effective management is essential to maintain quality of life, ensure treatment adherence, and optimise survival outcomes. This study aimed to investigate patient-reported experiences and preferences about information regarding side effects received during breast cancer care. Methods: An international multi-stakeholder expert group conducted an online patient survey assessing comprehensiveness, timing, and delivery modality of information regarding treatment-related side effects among patients undergoing primary therapy (surgery, radiation, and [neo]adjuvant chemotherapy) and endocrine therapy for early breast cancer. Descriptive analyses were performed. Results: From June-August 2023, 608 respondents from Brazil, France, Germany, Italy, Japan, and Spain completed the survey: 57.5 % were <50 years old, and all were or had been on endocrine therapy. Fatigue was the most reported side effect (47.0 % for primary and 42.3 % for endocrine therapy). A variable proportion of patients (14.4%-46.8 % across side effects) reported receiving information only after having experienced the side effect. Up to 43.6 % of respondents reported receiving insufficient or no information on side effects from their healthcare providers. Most patients reported preference for proactive communication from healthcare providers about side effects and prevention strategies. Respondents valued direct interactions with physicians and nurses and capitalised on a relevant role for peer-support, however utility of smartphone and web-based platforms to record and manage symptoms was acknowledged. Conclusion: The survey underscores critical needs and offers insight informing the provision of comprehensive and timely information on treatment-related side effects across the cancer survivorship continuum.

引用

页数：11

共 38 条

[1] Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T., Et al., Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 8, pp. 1194-1220, (2019)
[2] Miller K.D., Nogueira L., Devasia T., Mariotto A.B., Yabroff K.R., Jemal A., Et al., Cancer treatment and survivorship statistics, 2022, CA Cancer J Clin, 72, 5, pp. 409-436, (2022)
[3] Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 74, 3, pp. 229-263, (2024)
[4] Fujimoto R.H.P., Koifman R.J., Silva I.D., Survival rates of breast cancer and predictive factors: a hospital-based study from western Amazon area in Brazil, Ciência Saúde Coletiva, 24, pp. 261-273, (2019)
[5] Ueno T., Ichikawa D., Shimizu Y., Narisawa T., Tsuji K., Ochi E., Et al., Comorbid insomnia among breast cancer survivors and its prediction using machine learning: a nationwide study in Japan, Jpn J Clin Oncol, 52, 1, pp. 39-46, (2022)
[6] Dafni U., Tsourti Z., Alatsathianos I., Breast cancer statistics in the European union: incidence and survival across European countries, Breast Care, 14, 6, pp. 344-353, (2019)
[7] de Ligt K.M., Heins M., Verloop J., Ezendam N.P.M., Smorenburg C.H., Korevaar J.C., Et al., The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors, Breast Cancer Res Treat, 178, 3, pp. 703-711, (2019)
[8] Ewertz M., Jensen A.B., Late effects of breast cancer treatment and potentials for rehabilitation, Acta Oncol Stockh Swed, 50, 2, pp. 187-193, (2011)
[9] Agrawal S., Late effects of cancer treatment in breast cancer survivors, South Asian J Cancer, 3, 2, pp. 112-115, (2014)
[10] Kabirian R., Franzoi M., Havas J., C C., O T., C L., Et al., Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer, JAMA Netw Open [Internet], 6, 11, (2023)

← 1 2 3 4 →